Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Oct;22(5):941-52, ix.
doi: 10.1016/j.hoc.2008.07.002.

Diffuse large B-cell lymphoma

Jonathan W Friedberg  1 , Richard I Fisher
Affiliations
Review

Diffuse large B-cell lymphoma

Jonathan W Friedberg et al. Hematol Oncol Clin North Am. 2008 Oct.

Abstract

Diffuse large B-cell lymphoma (DLBCL) remains a curable lymphoma, with improved outcome resulting in large part from the incorporation of rituximab in standard regimens. The disease is heterogeneous clinically, morphologically, and molecularly. Recent insights into the molecular heterogeneity of DLBCL are beginning to yield novel therapeutics with significant promise for key subsets of patients. Although cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone chemotherapy with rituximab remains a standard therapeutic approach for most patients who have DLBCL, it is anticipated that novel agents will be included in treatment regimens for many patients in the near future.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression-free Survival of Patients Receiving Eight Cycles of CHOP Alone and Patients Receiving Three Cycles of CHOP plus Radiotherapy, According to the Number of modified IPI Risk Factors. From Miller et al. NEJM 339 (1): 21, Figure 3
Figure 2
Figure 2
(A) Event-free survival, (B) progression-free survival, and (C) overall survival with a median follow-up of 5 years in patients treated with CHOP, and R-CHOP in the GELA study. From Journal of Clinical Oncology, Vol 23, No 18 (June 20), 2005: pp. 4117-4126 Figure 1
See this image and copyright information in PMC

References

    1. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004 Aug 23;23(38):6524–6534. - PubMed
    1. Hartge P, Devesa SS. Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Res. 1992 Oct 1;52 19 Suppl:5566s–5569s. - PubMed
    1. Holford TR, Zheng T, Mayne ST, McKay LA. Time trends of non-Hodgkin's lymphoma: are they real? What do they mean? Cancer Res. 1992 Oct 1;52 19 Suppl:5443s–5446s. - PubMed
    1. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002 Aug 21;94(16):1204–1210. - PubMed
    1. Blinder V, Fisher SG. The role of environmental factors in the etiology of lymphoma. Cancer Invest. 2008 Apr–May;26(3):306–316. - PubMed

Publication types

MeSH terms